Shen et al. (2022) also found that FBXW7, by promoting eye absent homolog 2 (EYA2) degradation, could reduce the tumor mesenchymal phenotype and enables increased immune cell infiltration, thereby enhancing the response to anti-PD-1 therapy in a mouse tumor model. Mutations in FBXW7 have also been associated with sensitivity or resistance to immunotherapy in endometrial and pancreatic cancers, as analyzed using gene sequencing (Lin et al., 2021). This evidence concerns the gene FBXW7 and familial pancreatic carcinoma.